It's almost impossible to map out study budgets with absolute precision. Planning for the unexpected costs, such as those associated with slow enrollment, protocol amendments, and other contingencies—is vital.
Irina Petrova
Advertisement
Articles by Irina Petrova
Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. companies are turning to Russa after having secured approval for 108 trials there in 2018.
Advertisement
Latest Updated Articles
Lightship’s Approach to Accessible, Representative, and Impactful Clinical TrialsPublished: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with LightshipPublished: February 19th 2025 | Updated: February 26th 2025
- Examining the Impact of Exclusionary Behaviors on Team Dynamics
Published: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent AdoptionPublished: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol DeviationsPublished: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple MyelomaPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
3
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
4
How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
